Evidence map›Paper›PMID 41750259›Full record

ReviewBiomolecules2026

CXCR4: A Promising Novel Strategy for Lung Cancer Treatment.

Mengting Liao, Jianmin Wu, Tengkun Dai, Guiyan Liu, Jiayi Zhang, Yiling Zhu, Lin Xu, Juanjuan Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mengting LiaoDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.
Jianmin WuDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.
Tengkun DaiDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.
Guiyan LiuDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.
Jiayi ZhangDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.
Yiling ZhuDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.
Lin XuDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.ORCID 0000-0002-6889-0279
Juanjuan ZhaoDepartment of Immunology, Zunyi Medical University, Zunyi 563000, China.ORCID 0000-0001-9253-8083

Funding

National Natural Science Foundation of China 82272812
6 · The paper itself

Abstract

Lung cancer remains a major public health challenge due to high incidence and mortality. The chemokine receptor

Indexed as

Antineoplastic AgentsLung NeoplasmsReceptors, CXCR4AnimalsChemokine CXCL12Gene Expression Regulation, NeoplasticHumansMolecular Targeted TherapySignal TransductionTumor MicroenvironmentAntineoplastic AgentsChemokine CXCL12CXCR4 protein, humanReceptors, CXCR4CXCR4expression patternslung cancermechanism of actiontherapeutic target

Identifiers

PMID41750259
PMCPMC12938481

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.